Human Umbilical Cord-derived Mesenchymal Stem Cells

BIOLOGICAL3 trials

Sponsors

Shanghai East Hospital, Beijing 302 Hospital

Conditions

Decompensated CirrhosisIschemic Heart DiseaseLung InjuryNon-cardiac Surgery

Phase 1

Effect of Human Umbilical Cord-derived Mesenchymal Stem Cells on Non-cardiac Surgery-induced Lung Injury

Shanghai East HospitalIschemic Heart Disease, Lung Injury, Non-cardiac Surgery

Start: 2021-08-01End: 2023-12-31Target: 16Updated: 2023-12-19

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)

Beijing 302 HospitalDecompensated Cirrhosis

Start: 2022-03-22End: 2025-03-01Target: 12Updated: 2023-04-26

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)

Beijing 302 HospitalDecompensated Cirrhosis

Start: 2023-08-30End: 2025-08-30Target: 6Updated: 2023-08-09

Related Papers

Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights.

2025-07-295 citations

Human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis (MSC-DLC-1): a dose-escalation, phase I trial protocol

BMJ Open2023-12-013 citations